In summary, the pharmacological profiles of KIOM-MA and KIOM-MA128 were as follows: the reduction of clinical features and IgE production suggest that KIOM-MA and KIOM-MA128 are effective for the treatment of AD in a dose-dependent manner. The gene discussed is IGHE; the disease is Alzheimer disease.